Lu-177-trastuzumab

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameLu-177-trastuzumab

Drug Alias NameLu-177 labeled trastuzumab (Tarbiat Modares University)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugateRadiation-emitting products

Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists

TargetsReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryIran

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesTarbiat Modares University

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesTarbiat Modares University

Active IndicationsN/A

Inactive IndicationsBreast Neoplasms

Other Information

ATC CodeN/A